INNOCAN PHARMA Corp INNPF
The SEC does not publish structured financial data (XBRL) for INNOCAN PHARMA Corp, so there are no statement tables here.
This is common for foreign companies that trade over the counter and for filers that only submit documents.
Its filings are still listed below and on SEC EDGAR.
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| FWP | Free writing prospectus | Apr 3, 2026 | — |
| F-1/A | Filing | Apr 3, 2026 | — |
| FWP | Free writing prospectus | Mar 16, 2026 | — |
| F-1 | Registration statement (foreign issuer) | Mar 16, 2026 | — |
| RW | Filing | Feb 23, 2026 | — |
| EFFECT | Filing | Jan 30, 2026 | — |
| CORRESP | Letter to the SEC | Jan 27, 2026 | — |
| CORRESP | Letter to the SEC | Jan 27, 2026 | — |
| F-1/A | Filing | Jan 7, 2026 | — |
| FWP | Free writing prospectus | Jan 6, 2026 | — |
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- INNPF (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- Canada (Federal Level)
- Headquarters
- Calgary
- SEC CIK
- 1889791
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.